Aisling Capital, Others Inject $48M Into Roka Bioscience

Law360, New York (January 6, 2012, 5:19 PM EST) -- Life science private equity firm Aisling Capital joined OrbiMed Advisors LLC, New Enterprise Associates Inc. and Tarrant Capital IP LLC in issuing $47.5 million in Series D financing for molecular testing technology company Roka Bioscience, the company announced Friday.

Roka closed on $27.5 million of the financing in December and expects to complete the round later this year, bringing the company's total amount raised to $104.7 million since its founding in September 2009.

The terms of the financing were not disclosed.

“We are very pleased with...
To view the full article, register now.